JPRN-UMIN000021146招募中1 期
Phase I study of optimal dose and pharmacokinetics of a Uracil/Tegafur (UFT) plus oral leucovorin regimen after liver resection for colorectal liver metastasis - Phase I study of optimal dose and pharmacokinetics of a Uracil/Tegafur (UFT) plus oral leucovorin regimen after liver resection for colorectal liver metastasis
Oita university, faculty of medicine, department gastroenterology and pediatric surgery0 个研究点目标入组 18 人开始时间: 2016年2月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Active synchronous or metachronous malignancy other than carcinoma in situ 2.Serious postoperative complications 3.Serious coexisting illness A) Uncontrolled diabetes mellitus B) Uncontrolled hypertension C) History of myocardial infarction, unstable angina within 6 months prior to the registration D) Severe pulmonary dysfunction E) Liver cirrhosis 4.Ascites or pleural effusion needed to 5.Positive HBs antigen 6.Bleeding, paralysis, obstruction or ulcer of gastrointestinal tract 7.Pregnant or nursing 8.Severe mental disorders 9.Not suitable for participating in the study for any other Reason by the physician
研究者
相似试验
招募中
1 期
A Phase I study to evaluate the Pharmacokinetics and Safety of Letrozole LEBE in Healthy Post-menopausal Women.CTIS2023-503948-13-00aboratorios Farmaceuticos Rovi S.A.90
招募中
1 期
A First-in-Human Study of a Controlled Release Formulation of Lanreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620001261909Ascil Australia Pty LTD16
已完成
1 期
A First-in-Human Study of a new Controlled Release Formulation of Octreotide acetate in healthy male volunteersNeuroendocrine TumoursMetabolic and Endocrine - Other endocrine disordersCancer - Neuroendocrine tumour (NET)AcromegalyACTRN12620000108910Ascil Australia Pty Ltd8
已完成
1 期
A Phase 1 Study of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow®Nebulizer System in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis orProgressive Fibrosing Interstitial Lung DiseaseProgressive, Fibrosing Interstitial Lung DiseasesRespiratory - Other respiratory disorders / diseasesIdiopathic Pulmonary FibrosisACTRN12620001141932Avalyn Pharma Pty Ltd38
已完成
1 期
A Phase I/II, pharmacokinetics and dose-finding study of M121101 in patients with pincer nailPincer nailJPRN-jRCT2080224657Maruho co.,Ltd.68